$1.10 Million in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter

Share on StockTwits

Wall Street brokerages expect that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will post $1.10 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings. The lowest sales estimate is $800,000.00 and the highest is $1.40 million. AcelRx Pharmaceuticals reported sales of $1.49 million during the same quarter last year, which indicates a negative year over year growth rate of 26.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year sales of $4.83 million for the current financial year, with estimates ranging from $1.00 million to $11.00 million. For the next fiscal year, analysts expect that the firm will report sales of $19.90 million per share, with estimates ranging from $11.00 million to $30.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.93 million.

ACRX has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. Oppenheimer restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $6.00 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 2nd. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, LADENBURG THALM/SH SH initiated coverage on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 16th. They issued a “buy” rating and a $7.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $5.21.

In related news, insider Pamela P. Palmer bought 37,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The shares were bought at an average price of $2.75 per share, for a total transaction of $101,750.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Vincent J. Angotti bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 7th. The shares were bought at an average price of $2.90 per share, for a total transaction of $29,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,600 shares of company stock worth $193,192 in the last quarter. 25.50% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $1,676,000. FMR LLC lifted its position in shares of AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 273,644 shares during the period. BlackRock Inc. lifted its position in shares of AcelRx Pharmaceuticals by 2.7% during the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock valued at $2,271,000 after acquiring an additional 17,737 shares during the period. Granite Investment Partners LLC acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $182,000. Finally, Lincoln Capital Corp acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $116,000. Institutional investors own 8.39% of the company’s stock.

AcelRx Pharmaceuticals stock traded up $0.02 during trading hours on Friday, hitting $2.92. 100 shares of the stock were exchanged, compared to its average volume of 616,064. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The stock has a market capitalization of $184.83 million, a price-to-earnings ratio of -2.68 and a beta of 2.13. The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Further Reading: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply